Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/05/27 | 1,518 | 1,574 | 1,489 | 1,550 | +50 | +3.3% | 190,400 |
2021/05/26 | 1,483 | 1,507 | 1,460 | 1,500 | +18 | +1.2% | 98,500 |
2021/05/25 | 1,417 | 1,492 | 1,400 | 1,482 | +95 | +6.8% | 182,200 |
2021/05/24 | 1,445 | 1,445 | 1,370 | 1,387 | -75 | -5.1% | 140,500 |
2021/05/21 | 1,420 | 1,480 | 1,409 | 1,462 | +55 | +3.9% | 105,200 |
2021/05/20 | 1,410 | 1,437 | 1,377 | 1,407 | -26 | -1.8% | 122,900 |
2021/05/19 | 1,344 | 1,447 | 1,343 | 1,433 | +89 | +6.6% | 229,100 |
2021/05/18 | 1,277 | 1,353 | 1,271 | 1,344 | +94 | +7.5% | 174,000 |
2021/05/17 | 1,271 | 1,311 | 1,208 | 1,250 | +2 | +0.2% | 170,900 |
2021/05/14 | 1,192 | 1,261 | 1,188 | 1,248 | +56 | +4.7% | 109,500 |
2021/05/13 | 1,211 | 1,245 | 1,156 | 1,192 | -49 | -3.9% | 224,200 |
2021/05/12 | 1,290 | 1,313 | 1,195 | 1,241 | -58 | -4.5% | 273,200 |
2021/05/11 | 1,346 | 1,359 | 1,288 | 1,299 | -73 | -5.3% | 183,300 |
2021/05/10 | 1,343 | 1,382 | 1,336 | 1,372 | +16 | +1.2% | 56,400 |
2021/05/07 | 1,336 | 1,365 | 1,315 | 1,356 | +21 | +1.6% | 43,000 |
2021/05/06 | 1,410 | 1,410 | 1,325 | 1,335 | -49 | -3.5% | 114,300 |
2021/04/30 | 1,370 | 1,392 | 1,347 | 1,384 | +23 | +1.7% | 77,900 |
2021/04/28 | 1,412 | 1,420 | 1,345 | 1,361 | -63 | -4.4% | 163,800 |
2021/04/27 | 1,443 | 1,509 | 1,410 | 1,424 | -19 | -1.3% | 197,100 |
2021/04/26 | 1,390 | 1,460 | 1,370 | 1,443 | +53 | +3.8% | 150,300 |
2021/04/23 | 1,377 | 1,479 | 1,345 | 1,390 | +16 | +1.2% | 279,300 |
2021/04/22 | 1,317 | 1,378 | 1,299 | 1,374 | +84 | +6.5% | 168,500 |
2021/04/21 | 1,320 | 1,340 | 1,264 | 1,290 | -15 | -1.1% | 159,500 |
2021/04/20 | 1,275 | 1,355 | 1,256 | 1,305 | +10 | +0.8% | 149,100 |
2021/04/19 | 1,311 | 1,330 | 1,291 | 1,295 | +28 | +2.2% | 153,700 |
2021/04/16 | 1,247 | 1,269 | 1,224 | 1,267 | +20 | +1.6% | 63,200 |
2021/04/15 | 1,242 | 1,254 | 1,210 | 1,247 | -2 | -0.2% | 88,800 |
2021/04/14 | 1,242 | 1,259 | 1,227 | 1,249 | -6 | -0.5% | 88,000 |
2021/04/13 | 1,265 | 1,292 | 1,248 | 1,255 | -9 | -0.7% | 89,900 |
2021/04/12 | 1,297 | 1,307 | 1,263 | 1,264 | -38 | -2.9% | 61,800 |
2021/04/09 | 1,279 | 1,312 | 1,257 | 1,302 | +39 | +3.1% | 97,900 |
2021/04/08 | 1,273 | 1,273 | 1,205 | 1,263 | -9 | -0.7% | 196,800 |
2021/04/07 | 1,292 | 1,330 | 1,271 | 1,272 | -41 | -3.1% | 148,700 |
2021/04/06 | 1,298 | 1,314 | 1,273 | 1,313 | -7 | -0.5% | 136,100 |
2021/04/05 | 1,331 | 1,346 | 1,294 | 1,320 | +1 | +0.1% | 118,000 |
2021/04/02 | 1,405 | 1,405 | 1,302 | 1,319 | -88 | -6.3% | 338,500 |
2021/04/01 | 1,382 | 1,409 | 1,364 | 1,407 | +22 | +1.6% | 193,200 |
2021/03/31 | 1,330 | 1,431 | 1,302 | 1,385 | +63 | +4.8% | 321,800 |
2021/03/30 | 1,294 | 1,343 | 1,272 | 1,322 | +44 | +3.4% | 219,100 |
2021/03/29 | 1,368 | 1,370 | 1,256 | 1,278 | -72 | -5.3% | 384,100 |
2021/03/26 | 1,264 | 1,358 | 1,263 | 1,350 | +86 | +6.8% | 261,400 |
2021/03/25 | 1,380 | 1,380 | 1,260 | 1,264 | -122 | -8.8% | 434,100 |
2021/03/24 | 1,327 | 1,407 | 1,288 | 1,386 | +29 | +2.1% | 407,300 |
2021/03/23 | 1,410 | 1,430 | 1,345 | 1,357 | -39 | -2.8% | 287,300 |
2021/03/22 | 1,385 | 1,448 | 1,360 | 1,396 | +25 | +1.8% | 398,900 |
2021/03/19 | 1,251 | 1,385 | 1,242 | 1,371 | +111 | +8.8% | 333,900 |
2021/03/18 | 1,310 | 1,335 | 1,236 | 1,260 | -13 | -1% | 257,400 |
2021/03/17 | 1,235 | 1,312 | 1,210 | 1,273 | +24 | +1.9% | 331,900 |
2021/03/16 | 1,146 | 1,254 | 1,135 | 1,249 | +104 | +9.1% | 165,900 |
2021/03/15 | 1,130 | 1,149 | 1,120 | 1,145 | +21 | +1.9% | 53,300 |
951~
1000
件表示中 / 1585件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 49,600円 | - | - | - | - | 15.37倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
キッズバイオ | 11,500円 | - | - | - | - | 7.39倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞(SHED)用いた再生医療に力 |
カルナバイオ | 25,500円 | +13.5% | - | - | - | 2.22倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 73,100円 | +306.2% | - | 0.00% | 28.22倍 | 2.15倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
免疫生物 | 44,000円 | +13.4% | +44.0% | - | 19.06倍 | 3.21倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム